Wir sind mit live! Mehr erfahren

Standard BioTools

LAB

Börsenwert 247 Mio. $

0,6290 USD

-0,0294

4,47 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

1 Tag

-4,47 %

5 Tage

-8,84 %

1 Monat

-11,3 %

3 Monate

-26,65 %

6 Monate

-31,9 %

Seit Jahresbeginn

-50,47 %

1 Jahr

-51,24 %

5 Jahre

-88,11 %

10 Jahre

-85,51 %

Profil: Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.

Mitarbeiter: 389

Gesundheitswesen Medizintechnik

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 0 %

Neutral 100 %

Negativ 0 %

Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED

BOSTON, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced it has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED (“ARCHIMED”), a leading investment firm focused exclusively on healthcare industries.

Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED

Standard BioTools Provides Update on Sale of Mass Cytometry Business

Standard BioTools Enters into New Purchase Agreement with Element Biosystems, a Subsidiary of GMT Venture, After Determining GMT Venture's Unsolicited Acquisition Proposal as Superior Standard BioTools Enters into New Purchase Agreement with Element Biosystems, a Subsidiary of GMT Venture, After Determining GMT Venture's Unsolicited Acquisition Proposal as Superior

Standard BioTools Provides Update on Sale of Mass Cytometry Business

Standard BioTools Reports Second Quarter 2026 Financial Results

BOSTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026.

Standard BioTools Reports Second Quarter 2026 Financial Results

Standard BioTools Announces Sale of Mass Cytometry Business and Illumina's Buyout of Contingent Payments to Advance Merger with Treeline Biosciences

Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms

Standard BioTools Announces Sale of Mass Cytometry Business and Illumina's Buyout of Contingent Payments to Advance Merger with Treeline Biosciences

Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026

BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market close. About Standard BioTools Inc.

Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026

Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction

Highlights combined company's strong financial position with over $900 million expected at closing, Treeline's deep clinical-stage pipeline, planned 2027 data updates for TLN-121 and TLN-372, and expected new program clinical starts

Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction

LiveRamp Launches Agentic Partner Program to Fast-Track Agentic Deployments for Customers

SAN FRANCISCO--(BUSINESS WIRE)--LiveRamp (NYSE: RAMP), the leader in data collaboration, today announced LiveRamp Agent Builders (LAB), a new program to bring more partner-built agents into its network and accelerate marketers' ability to transform planning, measurement, activation, and data transformation with AI. During LAB's pilot period, brands will have access to agents from all of the AI companies participating in the program, enabling customers to focus on finding tools that create value.

LiveRamp Launches Agentic Partner Program to Fast-Track Agentic Deployments for Customers

LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Standard BioTools Inc. (NASDAQ: LAB) and Treeline Biosciences, Inc. Upon closing of the proposed transaction, Standard BioTools shareholders are expected to own approximately 16% of the combined company. Halper Sadeh encourages Standard BioTools shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 o.

LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders

Labrador Gold Announces 2026 Exploration Plans for Pacific Ridge's White Gold Projects

Vancouver, British Columbia--(Newsfile Corp. - June 11, 2026) - Pacific Ridge Exploration Ltd. (TSXV: PEX) (OTCQB: PEXZF) (FSE: PQW) ("Pacific Ridge" or the "Company") is pleased to report that Labrador Gold Corp. (TSXV: LAB) ("LabGold") has announced plans for its 2026 exploration programs for the Company's Mariposa and Eureka Dome gold projects in the White Gold District, Yukon.

Labrador Gold Announces 2026 Exploration Plans for Pacific Ridge's White Gold Projects

Labrador Gold to Host Investor Webinar on the Mariposa Gold Project in Yukon's White Gold District

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX Venture: LAB) ("Labrador Gold" or the "Company") is pleased to announce that it will host a live investor webinar on Wednesday, June 17, 2026, at 12:00 PM PT / 3:00 PM ET, featuring President and CEO Roger Moss and moderated by Cory Fleck of the KE Report. The webinar will provide investors with an in-depth overview of the Company's recently acquired Mariposa Gold Project, including its strategic location within the Yukon's prolific White Gold District, historical exploration results, the recently approved Class 1 permit, planned 2026 exploration activities and upcoming catalysts as the Company advances this district-scale gold opportunity.

Labrador Gold to Host Investor Webinar on the Mariposa Gold Project in Yukon's White Gold District

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt